GSE193541 nifurtimox A-549 1 v 3 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE193541_nifurtimox_A-549_1_v_3_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE193541_nifurtimox_A-549_1_v_3_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE193541_nifurtimox_A-549_1_v_3_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE193541_nifurtimox_A-549_1_v_3_human_up.

Results found

Linked to

 

Label

Description

 

Gene

MT-ND2 pseudogene 28

Gene

general transcription factor IIi pseudogene 1

Gene

thymosin beta 15C

Gene

H3 clustered histone 15

Gene

ANKRD42 divergent transcript

Gene

long intergenic non-protein coding RNA 1778

Gene

uncharacterized LOC105372424

Gene

leucine rich repeat containing 37 member A17, pseudogene

Gene

small nucleolar RNA, H/ACA box 12

Gene

RNA, U5A small nuclear 1

  • Gene

    MT-ND2 pseudogene 28


  • Gene

    general transcription factor IIi pseudogene 1


  • Gene

    thymosin beta 15C


  • Gene

    H3 clustered histone 15


  • Gene

    ANKRD42 divergent transcript


  • Gene

    long intergenic non-protein coding RNA 1778


  • Gene

    uncharacterized LOC105372424


  • Gene

    leucine rich repeat containing 37 member A17, pseudogene


  • Gene

    small nucleolar RNA, H/ACA box 12


  • Gene

    RNA, U5A small nuclear 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.